Member Login
  1. Stocks
    2. /
  2. Bausch Health Companies Inc. (NYSE: BHC)
    3. /

NYSE:BHC (Bausch Health Companies Inc.)

About BHC

A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology.
Financial Market Data copyright © 2025 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • Bausch Health Companies Inc. (NYSE: BHC) Latest News

    The Motley Fool
    Investing

    Will These Companies Be Back in Vogue in 2017?

    | Ryan Goldsman

    Will shares of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), BlackBerry Ltd. (TSX:BB)(NASDAQ:BBRY), or Bombardier, Inc. (TSX:BBD.B) be back in vogue in…

    Read more »

    Investing

    Checklist: How to Find a Great Stock

    | Karen Thomas, MSc, CFA

    Free cash flow, low debt levels, and strong shareholder returns are paramount to the success of an investment. CCL Industries…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: Should You Take a Contrarian Shot?

    | Andrew Walker

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is hitting new multi-year lows. Is the bottom in sight?

    Read more »

    The Motley Fool
    Investing

    Why I’m Avoiding Valeant Pharmaceutical Intl Inc. Like the Plague

    | Joey Frenette

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) could be many years away from seeing its stock rally.

    Read more »

    Investing

    Will Valeant Pharmaceuticals Intl Inc. Survive the Trump Presidency?

    | Alexander John Tun

    With President Trump openly critical of price-hiking pharmaceutical companies, can Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) survive the next four years?

    Read more »

    The Motley Fool
    Investing

    How 2017 Will Unfold for Valeant Pharmaceuticals Intl Inc.

    | Demetris Afxentiou

    A mountain of debt, difficult no-win decisions, and a potential battle with the Trump administration are just some of the…

    Read more »

    The Motley Fool
    Investing

    Explaining the Interest Costs of Valeant Pharmaceuticals Intl Inc.

    | Ryan Goldsman

    With crippling interest costs, shares of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) will implode by the end of 2017.

    Read more »

    The Motley Fool
    Investing

    Simple Math Doesn’t Work at Valeant Pharmaceuticals Intl Inc.

    | Ryan Goldsman

    Although Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) announced major news in the past week, this will not change the end result:…

    Read more »

    The Motley Fool
    Tech Stocks

    Valeant Pharmaceuticals Intl Inc. on Fire to Start the Year

    | Karl Utermohlen

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has made some huge sales in the new year, helping the company to offload some…

    Read more »

    The Motley Fool
    Investing

    On the Move! Valeant Pharmaceuticals Intl Inc. Rises Again

    | Demetris Afxentiou

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) announced the sale of some non-core assets this week which will help pay down the…

    Read more »

    Investing

    Valeant Pharmaceuticals Intl Inc. Just Sold Over US$2 Billion in Assets: What Now?

    | Jacob Donnelly

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is finally selling assets, but the proceeds don't cover enough of the mountain of debt…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceutical Intl Inc. Just Raised its Drug Prices Again

    | Joey Frenette

    Valeant Pharmaceutical Intl Inc. (TSX:VRX)(NYSE:VRX) is doing everything it can to raise money to pay back its debt. It's selling…

    Read more »